Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Hewlett Packard Enterprise Co (HPE) Price & Performance

Abeona Therapeutics IncTrade
Hewlett Packard Enterprise CoTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Hewlett Packard Enterprise Co — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Hewlett Packard Enterprise Co trades at $58.19 (market cap $72.01B). The key difference: Hewlett Packard Enterprise Co is far larger — about 171× Abeona Therapeutics Inc's market cap, and Hewlett Packard Enterprise Co pays a 1.05% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.

ABEOHPE
Market Cap
$421.19M$72.01B
Sector
HealthTechnology
52-Week High
$7.45$56.14
52-Week Low
$4.17$20.01
Enterprise Value
$276.10M$87.96B
Dividend Yield
1.05%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.

Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.

Hewlett Packard Enterprise Co

HPE stock trades at $57.72, up 5.58% in the last session, supported by a bullish technical outlook and strong earnings beats. Recent momentum is fueled by Morgan Stanley's upgrade citing AI infrastructure demand, with the stock near its 52-week high. Revenue growth accelerated to $34.3B in 2025, though net income margins compressed sharply to 0.16%. The consensus price target of $69.81 implies 21% upside, with analysts divided between Buy (46%) and Hold (51%) ratings.

Outlook: HPE benefits from AI server tailwinds and institutional accumulation, but high P/E (50.8) and volatile cash flows pose valuation risks. Key catalysts include Q2 2026 earnings (expected EPS $0.925) and execution in competitive AI hardware markets. Risks include debt growth (29.5% debt-to-assets) and margin pressure from rising investments.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Hewlett Packard Enterprise Co

Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.

Read more on HPE